Drug news
CHMP positive for Lifmior (etanercept) to treat same conditions as Enbrel.- Pfizer
The Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Lifmior, for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, axial spondyloarthritis (including ankylosing spondylitis and non-radiographic axial spondyloarthritis), plaque psoriasis and paediatric plaque psoriasis. The applicant for this medicinal product is Pfizer Limited.
Enbrel patents in the EU expired in February 2015.